Kanarb Use In Pregnancy & Lactation

Pregnancy: Drugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death when administered to pregnant women. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased foetal renal function; oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug. When pregnancy is detected, Kanarb Tablets should be discontinued as soon as possible. These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and foetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patient become pregnant, physicians should advise the patient to discontinue the use of Kanarb Tablets as soon as possible. Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria, and hyperkalemia.
Breast-feeding: It is not known whether Kanarb Tablets is excreted in human milk, but Kanarb Tablets was excreted in the milk of lactating rats; therefore, it is not recommended to administer Kanarb Tablets to nursing mothers. A decision should be made whether to discontinue nursing or discontinue Kanarb Tablets, taking into account the importance of the drug to the mother.